Compound profile
IGF-1 LR3
EmergingAlso known as: Long R3 IGF-1 · LR3-IGF-1
An engineered analog of insulin-like growth factor 1 with reduced binding to its natural binding proteins, giving it a longer half-life and greater potency than native IGF-1. Studied in animals as a research tool for IGF-1 receptor biology, not developed or tested as a human therapeutic.
Overview
IGF-1 LR3 is a laboratory-engineered variant of human IGF-1, built by researchers in the early 1990s to study IGF-1 receptor biology without the confound of the body's IGF-binding proteins, which normally bind circulating IGF-1 and buffer its activity. The modifications, an arginine substitution at position 3 and a 13-amino-acid extension at the front of the molecule, reduce its affinity for those binding proteins by roughly a thousandfold while leaving its ability to activate the IGF-1 receptor intact.
That combination makes it both more potent and longer-lasting than native IGF-1 in animal studies, since more of an administered dose stays free and active rather than getting mopped up by binding proteins. It was developed as a laboratory reagent, appearing in Australian research on diabetic rats and organ growth in guinea pigs, not as a candidate drug taken through clinical development.
It has since been adopted by the research-chemical and bodybuilding supplement markets as a purported mass-building and fat-loss peptide, a use case entirely disconnected from the animal physiology research it actually comes from. There is no published human trial data on IGF-1 LR3 of any kind.
Mechanism (plain language)
Binds and activates the IGF-1 receptor, triggering the PI3K/Akt pathway (protein synthesis) and MAPK/ERK pathway (cell proliferation), while its structural modifications drastically reduce sequestration by IGF-binding proteins, leaving more of the molecule free and active for longer.
How it works
Native IGF-1 circulates almost entirely bound to a family of IGF-binding proteins, which control how much free, active hormone reaches tissue at any given time. IGF-1 LR3's structural changes were specifically designed to disrupt that binding without affecting the molecule's ability to dock with and activate the IGF-1 receptor itself. Once bound to the receptor, it activates the same two downstream pathways as native IGF-1, PI3K/Akt, which drives protein synthesis in muscle, and MAPK/ERK, which drives cell proliferation.
Because so little of an administered dose gets absorbed by binding proteins, animal studies report LR3-IGF-1 is both more metabolically potent and longer-acting than an equivalent dose of native IGF-1, with a half-life extended from roughly 12 to 15 hours to an estimated 20 to 30 hours. This same property, being unregulated by the body's normal IGF-1 buffering system, is also the reason researchers use it as a laboratory tool to isolate IGF-1 receptor effects, and it is the underlying reason for concern about unchecked activation of that receptor at the tissue level.
What research suggests
Animal studies, largely in rodents and guinea pigs, confirm the analog is more potent and longer-lasting than native IGF-1 and can stimulate organ and tissue growth. No human studies of any kind, safety or efficacy, have been published.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Greater potency and longer half-life than native IGF-1
Its resistance to IGF-binding protein sequestration means animal studies report it as more metabolically potent and longer-acting than an equivalent dose of native IGF-1.
Demonstrated organ and tissue growth in animal studies
Infusion studies in guinea pigs and diabetic rats report stimulated organ growth and restored growth rates, illustrating strong IGF-1 receptor activation, though this is animal pharmacology data, not evidence of a desirable human outcome.
Uncertainties & risks
This compound was built as a laboratory tool to study receptor biology, not as a candidate drug, and there is zero human trial data. Its resistance to the body's normal IGF-1 binding-protein buffering system is also the basis for theoretical concerns about organ overgrowth and unchecked receptor activation with sustained use.
IGF-1 LR3's entire evidence base comes from animal physiology research designed to answer questions about receptor biology, not from any drug-development program, and no controlled human study of any kind has ever been conducted. Animal research describing organ growth from LR3-IGF-1 infusion is often cited approvingly by research-chemical sellers, but growth of internal organs in a research setting is a red flag for unsupervised human use, not a selling point. Because it resists the body's normal IGF-binding-protein buffering, it carries a distinct theoretical risk profile from native IGF-1, including concerns about hypoglycemia given IGF-1's insulin-like cross-reactivity, and about unchecked tissue growth with repeated or prolonged dosing. It is unregulated, unapproved, and has no established human dosing guidance grounded in actual trial data.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.